Trial Profile
A Pilot, Phase II, Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GW640385 When Administered With Ritonavir in Combination With NRTIs for 48 Weeks in HIV-1 Infected Adults.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Brecanavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 03 Apr 2013 Company changed from GlaxoSmithKline to ViiV Healthcare as reported by ClinicalTrials.gov.
- 31 Mar 2009 New trial record